Advertisement

DPIV/CD26 and FAP in Cancer: A Tale of Contradictions

  • Melanie L Sulda
  • Catherine A Abbott
  • Martin Hildebrandt
Part of the Advances in Experimental Medicine and Biology book series (volume 575)

Keywords

Melanoma Cell Mesothelial Cell Dipeptidyl Peptidase Tumour Suppressor Role Fibroblast Activation Protein 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abbott CA and Gorrell MD. (2002) In Ectopeptidases: CD13/Aminopeptidase N and CD26/Dipeptidylpeptidase IV in Medicine and Biology, (Eds, Langner, J. and Ansorge, S.) Kluwer/Plenum, New York, pp. 171–195.Google Scholar
  2. Abbott CA, McCaughan GW, Levy MT, Church WB and Gorrell MD. (1999) Binding to human dipeptidyl peptidase IV by adenosine deaminase and antibodies that inhibit ligand binding involves overlapping, discontinuous sites on a predicted beta propeller domain. Eur J Biochem. 266: 798–810.CrossRefPubMedGoogle Scholar
  3. Adams S, Miller GT, Jesson MI, Watanabe T, Jones B and Wallner BP. (2004) PT-100, a small molecule dipeptidyl peptidase inhibitor, has potent antitumor effects and augments antibody-mediated cytotoxicity via a novel immune mechanism. Cancer Res. 64: 5471–80.CrossRefPubMedGoogle Scholar
  4. Ajami K, Abbott CA, Obradovic M, Gysbers V, Kähne T, McCaughan GW and Gorrell MD. (2003) Structural requirements for catalysis, expression and dimerisation in the CD26/DPPIV gene family. Biochemistry USA. 42: 694–701.CrossRefGoogle Scholar
  5. Asada Y, Aratake Y, Kotani T, Marutsuka K, Araki Y, Ohtaki S and Sumiyoshi A, 1993, Expression of dipeptidyl aminopeptidase IV activity in human lung carcinoma. Histopathol. 23: 265–270.Google Scholar
  6. Bogenrieder T, Finstad CL, Freeman RH, Papandreou CN, Scher HI, Albino AP, Reuter VE and Nanus DM, 1997, Expression and localization of aminopeptidase A, aminopeptidase N, and dipeptidyl peptidase IV in benign and malignant human prostate tissue. Prostate. 33: 225–232.CrossRefPubMedGoogle Scholar
  7. Cheng HC, Abdel-Ghany M and Pauli BU, 2003, A novel consensus motif in fibronectin mediates dipeptidyl peptidase IV adhesion and metastasis. J Biol Chem. 278: 24600–24607.CrossRefPubMedGoogle Scholar
  8. Cheng JD, Valianou M, Canutescu A, Jaffe EK, Lee H-O, Wang H, Lai JH, Bachovchin WW and Weiner LM, 2005, Abrogation of fibroblast activation protein enzymatic activity attenuates tumour growth. Mol Canc Therap. 4: 351–360.Google Scholar
  9. Cordero OJ, Ayude D, Nogueira M, Rodriguez-Berrocal FJ and de la Cadena MP, 2000, Preoperative serum CD26 levels: diagnostic efficiency and predictive value for colorectal cancer. Br J Cancer. 83: 1139–1146.CrossRefPubMedGoogle Scholar
  10. de la Haba-Rodriguez J, Macho A, Calzado MA, Blazquez MV, Gomez MA, Munoz EE and Aranda E, 2002, Soluble dipeptidyl peptidase IV (CD-26) in serum of patients with colorectal carcinoma. Neoplasma. 49: 307–311.PubMedGoogle Scholar
  11. Ghersi G, Chen W, Lee EW and Zukowska Z, 2001, Critical role of dipeptidyl peptidase IV in neuropeptide Y-mediated endothelial cell migration in response to wounding. Peptides. 22: 453–458.CrossRefPubMedGoogle Scholar
  12. Ghersi G, Dong H, Goldstein LA, Yeh Y, Hakkinen L, Larjava HS and Chen WT, 2002, Regulation of fibroblast migration on collagenous matrix by a cell surface peptidase complex. J Biol Chem. 277: 29231–29241.CrossRefPubMedGoogle Scholar
  13. Gonzalez-Gronow M, Grenett HE, Gawdi G and Pizzo SV, 2005, Angiostatin directly inhibits human prostate tumor cell invasion by blocking plasminogen binding to its cellular receptor, CD26. Exp Cell Res. 303: 22–31.CrossRefPubMedGoogle Scholar
  14. Gonzalez-Gronow M, Grenett HE, Weber MR, Gawdi G and Pizzo SV, 2001, Interaction of plasminogen with dipeptidyl peptidase IV initiates a signal transduction mechanism which regulates expression of matrix metalloproteinase-9 by prostate cancer cells. Biochem J. 355: 397–407.CrossRefPubMedGoogle Scholar
  15. Goodman JD, Rozypal TL and Kelly T, 2003, Seprase, a membrane-bound protease, alleviates the serum growth requirement of human breast cancer cells. Clin Exp Metastasis. 20: 459–470.CrossRefPubMedGoogle Scholar
  16. Hoffman T, von Horsten S, Hama Y, Shingu K, Demuth H-U and Heiser U, 2003, Chronic Treatment with Dipeptidyl Peptidase IV (DPIV) inhibitors inhibits tumour metastasis in the MADB106 Adenocarcinoma rat model, In 3rd General Meeting of the International Proteolysis Society. Japan 2003.Google Scholar
  17. Houghton AN, Albino AP, Cordon-Cardo C, Davis LJ and Eisinger M, 1988, Cell surface antigens of human melanocytes and melanoma. Expression of adenosine deaminase binding protein is extinguished with melanocyte transformation. J Exp Med. 167: 197–212.CrossRefPubMedGoogle Scholar
  18. Huang Y, Wang S and Kelly T, 2004, Seprase promotes rapid tumor growth and increased microvessel density in a mouse model of human breast cancer. Cancer Res. 64: 2712–2716.CrossRefPubMedGoogle Scholar
  19. Huber MA, Kraut N, Park JE, Schubert RD, Rettig WJ, Peter RU and Garin-Chesa P, 2003, Fibroblast activation protein: differential expression and serine protease activity in reactive stromal fibroblasts of melanocytic skin tumors. J Invest Dermatol. 120: 182–188.CrossRefPubMedGoogle Scholar
  20. Iwata S and Morimoto C, 1999, CD26/dipeptidyl peptidase IV in context: the different roles of a multifunctional ectoenzyme in malignant transformation. J Exp Med. 190: 301–305.CrossRefPubMedGoogle Scholar
  21. Kajiyama H, Kikkawa F, Khin E, Shibata K, Ino K and Mizutani S, 2003, Dipeptidyl peptidase IV overexpression induces up-regulation of E-cadherin and tissue inhibitors of matrix metalloproteinases, resulting in decreased invasive potential in ovarian carcinoma cells. Cancer Res. 63: 2278–2283.PubMedGoogle Scholar
  22. Kajiyama H, Kikkawa F, Maeda O, Suzuki T, Ino K and Mizutani S, 2002a, Increased expression of dipeptidyl peptidase IV in human mesothelial cells by malignant ascites from ovarian carcinoma patients. Oncology. 63: 158–165.CrossRefPubMedGoogle Scholar
  23. Kajiyama H, Kikkawa F, Suzuki T, Shibata K, Ino K and Mizutani S, 2002b, Prolonged survival and decreased invasive activity attributable to dipeptidyl peptidase IV overexpression in ovarian carcinoma. Cancer Res. 62: 2753–2757.PubMedGoogle Scholar
  24. Kikkawa F, Kajiyama H, Ino K, Shibata K and Mizutani S, 2003, Increased adhesion potency of ovarian carcinoma cells to mesothelial cells by overexpression of dipeptidyl peptidase IV. Int J Cancer. 105: 779–783.CrossRefPubMedGoogle Scholar
  25. Merighi S, Mirandola P, Milani D, Varani K, Gessi S, Klotz K-N, Leung E, Baraldi PG and Borea A, 2002, Adenosine Receptors as Mediators of Both Cell Proliferation and Cell Death of Clutured Human Melanoma Cells. J Invest Dermatol. 119: 923–933.CrossRefPubMedGoogle Scholar
  26. Mueller SC, Ghersi G, Akiyama SK, Sang QXA, Howard L, Pineiro-Sanchez M, Nakahara H, Yeh Y and Chen WT, 1999, A novel protease-docking function of integrin at invadopodia. J Biol Chem. 274: 24947–24952.CrossRefPubMedGoogle Scholar
  27. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verastegui E and Zlotnik A, 2001, Involvement of chemokine receptors in breast cancer metastasis. Nature. 410: 50–56.CrossRefPubMedGoogle Scholar
  28. Pethiyagoda C, Welch D and Fleming T. (2001) Dipeptidyl peptidase IV (DPPIV) inhibits cellular invasion of melanoma cells. Clin Exp Metastasis. 18: 391–400.CrossRefGoogle Scholar
  29. Ramirez-Montagut T, Blachere NE, Sviderskaya EV, Bennett DC, Rettig WJ, Garin-Chesa P and Houghton AN, 2004, FAPalpha, a surface peptidase expressed during wound healing, is a tumor suppressor. Oncogene. 23: 5435–5446.CrossRefPubMedGoogle Scholar
  30. Rettig WJ, Garin-Chesa P, Healey JH, Su SL, Ozer HL, Schwab M, Albino AP and Old LJ, 1993, Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin. Cancer Res. 53: 3327–3335.PubMedGoogle Scholar
  31. Tan EY, Mujoomdar M and Blay J, 2004, Adenosine down-regulates the surface expression of dipeptidyl peptidase IV on HT-29 human colorectal carcinoma cells: implications for cancer cell behavior. Am J Pathol. 165: 319–330.PubMedGoogle Scholar
  32. Wesley UV, Albino AP, Tiwari S and Houghton AN, 1999, A role for dipeptidyl peptidase IV in suppressing the malignant phenotype of melanocytic cells. J Exp Med. 190: 311–322.CrossRefPubMedGoogle Scholar
  33. Wesley UV, McGroarty M and Homoyouni A, 2005, Dipeptidyl peptidase inhibits malignant phenotype of prostate cancer cells by blocking basic fibroblast growth factor signaling pathway. Cancer Res. 65: 1325–1334.CrossRefPubMedGoogle Scholar
  34. Wesley UV, Tiwari S and Houghton AN, 2004, Role for dipeptidyl peptidase IV in tumor suppression of human non small cell lung carcinoma cells. Int J Canc. 109: 855–866.CrossRefGoogle Scholar
  35. Yan L, Shahied L, Tang Y, Kesavan P and Nakada T, 2004, Tumor-Host Interactions. Preclinica. 2: 422–426.Google Scholar

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  • Melanie L Sulda
    • 1
  • Catherine A Abbott
    • 1
  • Martin Hildebrandt
    • 2
  1. 1.School of Biological SciencesFlinders UniversityAdelaideAustralia
  2. 2.Dept. of Hematology, Oncology and Tumor Immunology, Robert-Rössle-Klinik im HELIOS Klinikum Berlin BuchCharité Universitätsmedizin BerlinBerlinGermany

Personalised recommendations